Bioscience

Mesa-based Predictive Biomarker Sciences tests cancer drug

June 22, 2010

By Flinn Foundation

[Source: The Arizona Republic] – A Mesa-based company that markets a drug-analysis technology has completed its first examination of an investigational cancer drug being developed by a Canadian biotechnology company.

Predictive Biomarker Sciences, a for-profit company partly owned by Phoenix-based Translational Genomics Research Institute, analyzed a drug candidate being developed by Ottawa, Ontario-based PharmaGap. The analysis suggested that PharmaGap’s potential drug, called GAP-107B8, attacks the membrane of colon cancer cells while having less impact on non-cancerous cells.

For more information: Mesa-based Predictive Biomarker Sciences tests cancer drug